Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Electra Battery Materials Corporation welcomed the U.S. Department of Commerce's new rule restricting exports of battery black mass, aiming to keep critical minerals within the U.S. This aligns with Electra's strategy to develop domestic refining capacity for nickel and recycled battery materials, addressing supply chain and national security conce…
Cerenome, Inc., through its subsidiary CNSide Diagnostics, has selected XiFin Empower RCM to provide AI-driven revenue cycle management and clearinghouse services for its CNSide cerebrospinal fluid assay platform. This partnership is designed to streamline billing processes, including addressing backlog claims, and enable scalable test volume growt…
Cronos Group reported its second quarter 2026 results with a 51% year-over-year increase in net revenue on a constant-currency basis, driven by record revenues in Canada, Israel, and international markets like Germany. The company achieved record gross profit and Adjusted EBITDA, significantly improved net income, and reduced share count through re…
Lexicon Pharmaceuticals completed enrollment for its pivotal Phase 3 SONATA-HCM study investigating sotagliflozin for hypertrophic cardiomyopathy, expects topline results in Q1 2027, and is nearing completion of NDA resubmission activities for ZYNQUISTA® in type 1 diabetes. The company also reported a net loss for Q2 2026 driven by increased R&D sp…
Kelly Services, a specialty talent solutions provider listed on Nasdaq, announced its second-quarter 2026 results showing a 5.8% year-over-year revenue decline with improving trends across its Enterprise Talent Management (ETM) and Science, Engineering & Technology (SET) segments. Operating earnings were $16.1 million with adjusted EBITDA margin im…
Compass Therapeutics reported second quarter 2026 financial results and provided corporate updates, highlighting positive tovecimig Phase 2/3 data and expected FDA feedback this quarter. The company is advancing clinical trials for several bispecific antibody candidates targeting cancers, including expansions for CTX-8371 and initiation of CTX-471 …
SAB Biotherapeutics reports Q2 2026 financial results highlighting progress in their SAB-142 immunotherapy for type 1 diabetes. The SAFEGUARD Phase 2b trial is on track with over 60 clinical sites activated and enrollment expected to complete by Q4 2026, with topline data anticipated in the second half of 2027. The company also secured a grant for …
Nayax Ltd., a Nasdaq-listed global commerce enablement and payments platform, has filed an application with the Connecticut Department of Banking to establish Nayax America Bank Inc., a non-depository innovation bank headquartered in Connecticut. The new bank, owned by Nayax USA Holdings, aims to offer embedded financial services such as corporate …
InflaRx N.V. announced its second quarter 2026 financial results alongside key clinical and strategic updates. The company is advancing its oral C5aR inhibitor, izicopan, targeting ANCA-associated vasculitis (AAV) and select renal diseases, with Phase 2 clinical preparations ongoing. InflaRx is exploring regulatory strategies following the European…
ZenaTech, Inc., a Nasdaq-listed AI and drone technology company, announced the acquisition of Galena-Benchmark Engineering, a civil engineering and land surveying firm based in Idaho. This marks ZenaTech's 27th Drone as a Service acquisition, expanding its presence into its 13th U.S. state. The acquisition aims to broaden ZenaTech's service offerin…
RXO shares jumped sharply in pre-market trading after the freight brokerage reported second-quarter revenue and earnings that topped analyst forecasts and accompanied those results with an optimistic third-quarter outlook. Volume growth in core brokerage operations and market share gains powered the top-line beat, while elevated analyst expectation…
Dave stock fell sharply in pre-market trading despite beating revenue and adjusted EPS expectations for the second quarter of 2026. While revenue rose 30% year-over-year and management increased full-year guidance, sizable non-cash charges and a large recent run-up in the share price triggered a sell-the-news reaction.
U.S. stock futures were little changed early Thursday as investors monitored reports about a possible agreement to reopen the Strait of Hormuz and wrestled with renewed doubts about the durability of AI-driven spending. Gains in select software and industrial names were offset by weakness in semiconductor and data storage stocks after quarterly res…
Celsius Holdings saw its stock dive in pre-market trade after releasing second-quarter 2026 results that fell short of analyst expectations across profitability and revenue metrics. While companywide revenue rose year-over-year, the core CELSIUS brand posted a double-digit decline, and operating margins narrowed sharply, prompting renewed analyst c…
Alterity Therapeutics, a clinical-stage biotechnology company focused on neurodegenerative diseases, announced that CEO Dr. David Stamler will present at the Canaccord Genuity Growth Conference on August 11, 2026. The company is preparing for a Phase 3 pivotal trial of ATH434 for Multiple System Atrophy (MSA), having shown positive Phase 2 results.…
On Aug. 6, Keurig Dr Pepper reported second-quarter results that exceeded analysts' expectations for both revenue and adjusted earnings per share, driven by strength in its soda and energy beverage portfolios. The company maintained its full-year outlook and reiterated 2026 net sales and adjusted EPS targets as it continues to integrate the JDE Pee…
ConocoPhillips reported second-quarter adjusted earnings that exceeded analyst forecasts, benefiting from stronger crude prices and internal cost reductions even as oil and gas production fell year-over-year. The company cited elevated Brent averages and ongoing regional tensions that have pressured supply chains for some U.S. producers with Middle…
SpaceX reported rapidly improving economics from its AI investments and faster-than-expected revenue growth, but heavy ongoing capital expenditures and investor unease over how long Starlink can underwrite the spending drove the stock sharply lower. Management says new compute deployments are delivering paybacks in under a year and that AI contract…
Warner Bros. Discovery reported second-quarter revenue of $8.72 billion, missing the LSEG estimate of $9.29 billion. The shortfall was driven by a 39% drop in studio revenue and a 22% decline in advertising sales tied to the absence of NBA broadcasts and lower domestic linear TV audiences. Streaming revenue rose 10%, helping deliver a surprise 6-ce…
Appian Corporation announced its financial results for Q2 2026, showing 19% year-over-year total revenue growth to $203.3 million driven by increased cloud subscriptions and professional services. The company improved its GAAP operating loss compared to the prior year and recorded a significant increase in non-GAAP operating income and adjusted EBI…
Lifetime Brands, Inc. announced its financial results for Q2 2026, reporting net sales growth of 7.4% year-over-year and significant earnings improvement driven by a $40.1 million tariff refund. The company repaid $40 million in term debt, showed robust growth in warehouse club and e-commerce channels, and reaffirmed net sales guidance while raisin…
Tarsus Pharmaceuticals announced robust second quarter 2026 financial results driven by 69% year-over-year growth in net product sales of their FDA-approved eye drop XDEMVY for Demodex blepharitis. The company increased its full-year sales guidance and advanced its pipeline with the pending acquisition of Alkeus Pharmaceuticals, adding a Phase 3 cl…
Ocugen provided a business update detailing FDA clearance to initiate its Phase 3 trial for OCU410 on geographic atrophy, received RMAT designation, secured a licensing agreement for OCU400 in the Middle East and North Africa, and closed a $130 million convertible senior notes financing. They remain on track for key data readouts in 2027 for their …
Tarsus Pharmaceuticals announced a $125 million private investment in public equity (PIPE) financing alongside its pending acquisition of Alkeus Pharmaceuticals. The financing garnered participation from existing and new institutional investors, supporting Tarsus' plans to advance clinical development and commercial activities primarily in ophthalm…
Tarsus Pharmaceuticals announced its definitive agreement to acquire Alkeus Pharmaceuticals, a private biotech focused on retinal diseases, for approximately $450 million upfront plus potential milestones and royalties. The acquisition adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational drug targeting Stargardt disease—a sig…
